Purpose Pelvic radiotherapy (PRT) is known to adversely affect bowel function (BF) and patient well-being. This study characterized long-term BF and evaluated quality of life (QOL) in patients receiving PRT. Methods Data from 252 patients were compiled from two North Central Cancer Treatment Group prospective studies, which included assessment of BF and QOL by the BF questionnaire (BFQ) and Uniscale QOL at baseline and 12 and 24 months after completion of radiotherapy. BFQ scores (sum of symptoms), Uniscale results, adverse-event incidence, and baseline demographic data were compared via t test, χ 2 , Fisher exact, Wilcoxon, and correlation methodologies.
Introduction
Pelvic radiotherapy is used in a diverse group of patients with various malignancies. The most common adverse effects involve the gastrointestinal tract and can be categorized as acute or long-term effects.
Acute gastrointestinal adverse effects due to irradiation of the small and large bowel occur during or shortly after pelvic radiotherapy and generally resolve within 6 weeks after treatment completion [1] [2] [3] [4] [5] . Acute effects include diarrhea, cramping, and tenesmus. Predictors include patient characteristics, tumor factors, and radiation dose [6, 7] . Chemotherapy and surgery can also affect the timing, severity, and duration of these acute events [8] . Studies have investigated the effectiveness of cholestyramine, olsalazine, sucralfate, glutamine, and octreotide to minimize acute toxicities [9] [10] [11] [12] [13] . To date, no agent tested in a randomized controlled trial has been shown effective with an acceptable adverse-effect profile. Cholestyramine (vs placebo) did reduce diarrhea but caused unacceptable levels of abdominal cramping [9] .
Long-term effects occur and persist for weeks to months after completion of treatment, may be permanent, and may have a considerable impact on quality of life (QOL). These can involve the small and large bowel, particularly the rectum. Small-bowel effects include pain, nausea, malabsorption, stricture, obstruction, fistulae, and abscesses [14] . Large-bowel effects include bleeding, frequency, urgency, stricture, fistulae, and fecal incontinence [15] . Chronic gastrointestinal toxicity may be a consequence of acute damage [16] . Long-term bowel function after radiotherapy has been studied for rectal, prostate, and gynecologic cancers [8, [17] [18] [19] [20] [21] [22] [23] .
The development of late bowel toxicity is related to the radiation dose and irradiated bowel volume [24] [25] [26] [27] , resulting in recommendations of dose constraints [26, 27] . This relationship between dose-volume and toxicity may be further affected by characteristics of surgery, chemotherapy, sex, age, and baseline comorbid conditions.
The current study, approved by the Mayo Clinic Institutional Review Board, aimed to characterize the long-term bowel function of patients treated in two completed North Central Cancer Treatment Group (NCCTG) phase III, double-blind trials whose purposes were to assess the effectiveness of glutamine (NCCTG 969256) [12] and octreotide (N00CA) [13] . Neither trial demonstrated efficacy in the prevention of acute diarrhea associated with pelvic radiotherapy. The goals of the current study were to explore the relationship of long-term bowel function and symptoms with baseline characteristics, treatment, recorded adverse events, and QOL.
Methods

Patient population and treatment
The study population consisted of 254 patients. The glutamine trial accrued 129 patients from February 1998 through October 1999. Patients received oral glutamine or placebo twice daily during radiotherapy and for 2 weeks after completion of treatment. The octreotide trial accrued 125 patients from May 2002 through October 2005. Patients received subcutaneous injections of depot octreotide acetate or placebo at the beginning of radiotherapy and on day 29 of treatment. Eligibility and study treatment criteria have been reported previously [12, 13] . Patients had histologic proof of cancer in the pelvis and had a planned course of definitive or adjuvant treatment of 45 to 53.5 Gy in 1.7-to 2.1-Gy fractions to the entire pelvis. The superior field border could not lie superior to the L4-5 interspace nor inferior to the sacroiliac joints. Physicians were allowed to boost primary tumor or tumor bed as indicated.
Data collection and assessment of bowel function
Baseline characteristic data were obtained. These included patient age, sex, race, primary disease site, history of rectal resection before radiotherapy, and adjunct treatment.
Toxicity was assessed during and after treatment using the National Cancer Institute Common Toxicity Criteria version 2.0 [28] . Patient-reported incidence of problematic bowel function symptoms was assessed using the bowel function questionnaire (BFQ) [12, 13, 29] (Appendix). Brief descriptions of evaluated symptoms are in Table 1 . Each study used the singleitem Uniscale measure [30] to record overall QOL on a linear scale (glutamine trial) or numeric scale (octreotide trial). Both versions of this measure have been validated and shown to be analogous to one another [31] . Normative data have been reported [32] . The BFQ and Uniscale, used successfully in other clinical trials [11] [12] [13] , were completed at baseline, weekly during radiotherapy, weekly for 4 weeks after treatment, and at 12 and 24 months after completion of radiotherapy.
Statistical analysis
The primary goal of this pooled analysis was to investigate long-term bowel function. The primary end point was the BFQ score at 24 months. Secondary goals and end points included investigation of BFQ score at 12 months, Uniscale score at 12 and 24 months, and relationships of both baseline characteristics and adverse events to QOL and long-term bowel function. Individual symptoms in the BFQ were assigned a value of 1 if the symptom was experienced and the total BFQ score (sum of values) was calculated (range 0-9). The score of the Uniscale was the number indicated by the patient (range 0-100, where 100 was best QOL). Patients were categorized as having clinically deficient QOL if the Uniscale score was less than or equal to 50 [33] . Changes from baseline were calculated for the total BFQ and Uniscale scores. The adverse-event profile per patient was characterized dichotomously according to the maximum adverse-event grade (<2 vs ≥2; <3 vs ≥3).
Two-sided hypotheses tests were conducted using type I error of α=0.05. Scores and changes from baseline at 12 and 24 months were assessed using single-sample t tests. End points were compared between treatments and baseline characteristic categories. Kruskal-Wallis or Wilcoxon methodologies were applied to continuous end points and χ 2 or Fisher exact methodologies were applied to discrete end points. Spearman/Pearson correlations were used to determine relationships between BFQ and Uniscale scores.
Results
Two patients were excluded because of missing QOL data; therefore, 252 patients were included in this analysis. Baseline patient characteristics are presented in Table 2 . BFQ results were available for 249 patients at baseline, 178 patients at 12 months, and 148 patients at 24 months. We compared the patients who completed BFQs at baseline, 12 months, and 24 months and observed no differences in the distribution of baseline characteristics of age, race, sex, prior rectal resection, 5-fluorouracil use, or location of primary tumor. Baseline Uniscale, total BFQ score, and frequency of each BFQ symptom were balanced between investigational and placebo arms (data for BFQ symptoms not shown).
No statistically significant differences were identified between intervention and placebo groups regarding mean BFQ score at 12 months (2.0 vs 1.6; P=0.31) and 24 months (1.7 vs 1.6; P=0.97) or change from baseline in mean BFQ score at 12 months (1.1 vs 0.5; P=0.12) or 24 months (0.7 vs 0.5; P=0.87). Comparisons of analogous Uniscale results also showed nonsignificant differences. Thus, the data were analyzed without separation by treatment group. Results indicate a decline in bowel function over time. Primary end point results showed patients had a mean BFQ score of 1.6 at 24 months (P<0.001). This significant difference was also present at 12 months (1.8; P<0.001). Significant mean BFQ changes from baseline also existed at both 24 and 12 months (0.59 and 0.80, respectively; P<0.001).
Incidence of specific symptoms of long-term bowel dysfunction increased from baseline. Figure 1 shows the percentage of patients with each individual BFQ symptom. The most common symptom was urgency, occurring in almost half of patients at 12 months after treatment. Symptoms occurring in greater than 20 % of patients were urgency, stool-gas confusion, clustering, and cramping. Statistically significant increases from baseline to 12 months were observed for total BFQ score (1.1 vs 1.8; P<0.001), incontinence (2.4 vs 9.6 %; P=0.001), protective clothing (1.2 vs 9.1 %; P<0.001), stoolgas confusion (14.2 vs 22.7 %; P=0.02), urgency (29.0 vs 48.3 %; P<0.001), and cramping (11.7 vs 21.7 %; P=0.005). Statistically significant increases from baseline to 24 months were observed for total BFQ score (1.1 vs 1.6; P<0.01), incontinence (2.4 vs 9.5 %; P=0.002), clustering (19.5 vs 28.4 %; P=0.04), and the need for protective clothing (1.2 vs 8.1 %; P<0.001). A slight decrease in total BFQ score occurred between 12 and 24 months (mean, 1.8 vs 1.6; P= 0.53). The incidence frequency of each BFQ symptom also decreased, although urgency had the only statistically significant decrease (48.3 vs 36.7 %; P=0.04). Figure 2 illustrates the percentage of affected patients with number of symptoms, stratified by time point. Many patients had no symptoms at baseline, 12 months, and 24 months [n= 121 (48.6 %), n=64 (36.0 %), and n=57 (38.5 %), respectively]. More patients had five or more symptoms at 12 months (13 %) and 24 months (10 %) than at baseline (2 %). At BFQ bowel function questionnaire, QOL quality of life, RT radiotherapy a Of the 57 patients treated with 5-fluorouracil, 53 had rectal cancer, 2 had anal cancer, 1 had bladder cancer, and 1 had gynecologic cancer b Potential scores ranged from 0 to 9 c Potential scores ranged from 0 to 100 baseline, 170 patients (67.5 %) had a BFQ score of 0 or 1. At 12 months, 81 (65.9 %) had fewer than two symptoms. At 24 months, 62 (61.4 %) had fewer than two symptoms.
Baseline characteristics were assessed to determine predictiveness. Characteristics associated with worse longterm bowel function were female sex, prior anterior resection of the rectum, use of 5-fluorouracil chemotherapy, and a primary rectal tumor ( Table 3) .
The relationship between acute toxicity and long-term bowel function was explored. Patients with grade 3 or greater acute bowel toxicity had significantly worse long-term bowel function, as measured by BFQ score at 24 months, than their lowergrade counterparts. Acute bowel toxicity grade was defined as the maximum grade of diarrhea, abdominal cramping, constipation, rectal bleeding, or tenesmus experienced by a patient. Patients with maximum acute bowel toxicity of less than grade 3 had a mean BFQ score of 1.23 at 24 months, whereas patients with acute grade 3 or greater toxicity had a mean score of 3.09 (P<0.001). Patients who had grade 2 or higher toxicity also had significantly greater incidence of clustering, stool-gas confusion, liquid stools, and cramping at 12 months (P≤0.01) (data not shown).
Uniscale scores had poor correlation with BFQ scores (r= −0.26 at 12 months; r=−0.17 at 24 months). Changes from baseline in Uniscale score at 12 and 24 months were not significant. Patients with clinically deficient QOL scores at baseline did not have significantly worse mean BFQ scores than those with non-deficient QOL at 12 months (2.7 vs 1.7; P=0.07) or at 24 months (2.2 vs 1.6; P=0.22). Table 4 contains mean Uniscale scores according to symptom incidence. At 12 months, significantly lower Uniscale scores occurred for those experiencing nocturnal bowel movements, clustering, the need for protective clothing, stool-gas confusion, liquid bowel movements, and cramping. At 24 months, significantly lower scores occurred for those experiencing clustering. Also at 24 months, significantly higher scores were reported by patients who did not experience a grade 2 or higher bowel toxicity grade (87.5 vs 80.6; P=0.02).
Discussion
This trial aimed to define long-term bowel function after pelvic radiotherapy and to identify factors that might predict worse bowel function. We measured patient-reported symptoms, an established, effective modality for collecting adverse-effect information [29, 34] . For our patients, pelvic radiotherapy resulted in worse long-term bowel function. Greater acute toxicity, female sex, location of primary tumor, history of rectal resection before radiotherapy, and treatment with 5-fluorouracil were all predictive of long-term bowel dysfunction. We noted Fig. 1 Incidence of bowel function symptoms. BFQ bowel function questionnaire Fig. 2 Distribution of BFQ scores. BFQ bowel function questionnaire improvement in the total BFQ score and diminished frequency of symptoms between 12 and 24 months, although differences were not statistically significant. Lastly, we observed that while many patients had no late-term bowel toxicity, a small number of patients had multisymptom dysfunction (Fig. 2) . Removal of BFQ scores greater than 5 resulted in a mean change from baseline at 24 months of .2 (P=0.17). Therefore, the increase in BFQ scores in a small number of patients accounted for most of the decline in bowel function in the population.
Most reports of poor long-term bowel function after pelvic radiotherapy describe postoperative patients with primary rectal cancer. Kollmorgen and colleagues [29] reported that patients were more likely to have bowel dysfunction, as measured by frequency, clustering, nocturnal bowel movements, incontinence, protective clothing, and inability to defer stooling. Univariate analysis revealed that age, sex, and length of follow-up had no significant effects on frequency of bowel movements and incontinence. Lundby et al. [35] found that patients had significantly worse bowel function, manifested as frequency, incontinence, urgency, protective clothing use, loose consistency, and inability to differentiate between stool and gas. Univariate analysis for possible predictors of bowel function was not reported. Similarly, Dahlberg et al. [36] reported that patients enrolled in the Swedish Rectal Cancer Trial had higher stool frequency and more commonly had emptying difficulties, incontinence, urgency, and toilet dependence.
The present study is unique in that patients had various primary cancers. Data were collected prospectively, eliminating potential recall bias and allowing standardized symptom BFQ bowel function questionnaire, RT radiotherapy a Two patients had a location of "other" and were excluded from this analysis b Significant P values indicate a difference in the incidence distributions among the three groups. It does not indicate pairwise differences c P value indicates significance of rectum vs prostate scores and frequencies reporting. Analyses were performed to identify patterns and possible predictors of bowel dysfunction in order to identify at-risk populations. Inclusion of patients with various pelvic cancers allowed assessment of the association between the type of cancer treated and subsequent toxicity. Pelvic radiotherapy parameters were broadly defined. Because few patients are treated using protocols that specify radiotherapy parameters in detail, our results likely reflect what would be observed in clinical practice. A limitation of our study is that correlation between specific radiotherapy techniques and subsequent toxicity could not be determined. Despite this limitation, our investigation provides useful data that can be applied to patients receiving pelvic radiotherapy. Further investigation into the consequences of dose and field arrangement is warranted.
Similar to prior reports [29, 35, 36] , bowel function in our population was worse 2 years after radiotherapy than at baseline. Importantly, long-term bowel symptoms persisted only in a small subset of the population. Symptoms appeared better at 24 months than at 12 months, implying that bowel function may continue to improve for at least 2 years after treatment. This has implications for patient counseling, particularly for patients whose symptoms are severe enough to consider ostomy for symptom control.
Conclusion
Pelvic radiotherapy is associated with long-term bowel dysfunction. However, a substantial proportion of patients have no long-term symptoms and a small subset of patients have clinically significant, multisymptom dysfunction. Long-term bowel toxicity, as measured by the BFQ score, did not significantly affect patient-reported QOL. Several factors may predict long-term bowel dysfunction, including presence and severity of acute toxicity, female sex, location of primary tumor, history of rectal resection, and treatment with 5-fluorouracil. Identification of patients at high risk of long-term bowel dysfunction can direct future research toward decreasing acute rectal toxicity and provide clinicians with information relevant for patient counseling. Furthermore, we hope that this meta-analysis encourages similar research for other disease sites and treatment modalities, so that clinicians can better define and continue to improve the impact of treatment on our patients. 
